GE
Danaher Prices $3.97B Senior Notes Offering
The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
Danaher Q3 Revenues Up 4 Percent
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
Danaher Offering €6.20B in Senior Notes
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
Life Sciences, Diagnostics Drive Danaher Q2 Revenues Up 4 Percent
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
Cowen Initiates Coverage of Horizon Discovery at Outperform
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.